2024-09-28 - Analysis Report
## CVS Health Corp (CVS) Stock Analysis Report

**1. Performance Comparison with S&P 500:**

CVS Health Corp (CVS) has significantly underperformed the S&P 500 (VOO) over the given period. The cumulative return of CVS is -33.47%, while the S&P 500 has achieved a return of 134.22%. This results in a divergence of -167.69, indicating CVS has significantly lagged behind the market benchmark.  

**Company Overview:** CVS Health Corp is a healthcare company that operates retail pharmacies, pharmacy benefit management (PBM) services, and health care services. 

**2. Recent Price Action:**

* Closing Price: $59.01
* 5-day Moving Average: $58.13
* 20-day Moving Average: $57.76
* 60-day Moving Average: $58.22

CVS is currently trading above its 5-day, 20-day, and 60-day moving averages, indicating a potential short-term uptrend. 

**3. Technical Indicators:**

* **RSI:** 57.26 - The RSI is slightly above the neutral level of 50, suggesting CVS is neither overbought nor oversold. 
* **PPO:** 0.28 - The PPO is positive, indicating a bullish signal.
* **Delta_Previous_Relative_Divergence:** -2.6 - The recent (20-day) relative divergence has decreased, showing a potential short-term bearish trend.
* **Expected_Return:** 0.0% - The expected return over the next 5 years is 0%, implying a low potential for growth based on current data.

**4. Recent Earnings and Outlook:**

| Date | EPS | Estimated EPS |
|---|---|---|
| 2024-08-07 | 1.83 | 1.73 |
| 2024-05-01 | 1.31 | 1.7 |
| 2024-02-07 | 2.12 | 2.01 |
| 2023-11-01 | 2.21 | 2.13 |
| 2023-08-02 | 2.21 | 2.12 |

CVS has consistently surpassed analysts' earnings estimates in recent quarters. The latest earnings report for Q2 2024 showed EPS of 1.83, exceeding the expected EPS of 1.73. This positive trend indicates a healthy financial performance.

**5. News and Recent Issues:**

* **Recent Market Outlook:** 
    * CVS has been facing headwinds from inflation and the slowing economy, impacting consumer spending on healthcare goods.
    * However, CVS's core PBM business remains resilient, driving revenue growth.
    * The company is focused on expanding its healthcare services, including digital health initiatives, to diversify its revenue streams.
* **Analyst Opinions and Performance Highlights:**
    * Finbold reports that CVS has a "Hold" rating with a consensus target price of $65.90.
    * Analysts are generally optimistic about CVS's long-term growth potential, particularly in the PBM and healthcare services segments.

**6. Overall Analysis:**

CVS Health Corp has underperformed the market in recent years, but the company's core PBM business remains strong and its recent earnings performance has been positive. The company's focus on expanding its healthcare services and digital health initiatives suggests potential for growth. Technical indicators are mixed, indicating a potential for both short-term upside and downside. Analysts remain cautiously optimistic about CVS's future prospects.

**7. Conclusion:**

Overall, CVS Health Corp presents a mixed picture for investors. While the company faces challenges from the macro-economic environment, its strong core business and growth initiatives provide reasons for optimism. Investors should carefully consider the risks and opportunities before making any investment decisions.
